fashion -WSS

fashion

author：hotspot 2025-10-02 19:20:28 - browse：931

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

focus

WSS

FDA approves first new drug developed for postpartum depression

A public health expert passes on football's full body collisions for youths

What we’ve learned from the Aduhelm mess

How to fix the rural physician shortage in the U.S.

Medical mystery: When a cough is not just a cough

Medical mystery: When a cough is not just a cough

explore

fashion

knowledge

The high cost of giving birth even with insurance

BioAge raises $170M for combination therapy with Zepbound

Activists slam private health insurers over coverage restrictions

Novo pauses ads for weight loss drug Wegovy amid demand

Medicare details structure of new drug price negotiation program

What should King Charles tell the public about his cancer?

Walensky prepares to leave CDC — and Congress — behind

The Readout: Gilead, Bernie Sanders, and other pharma news

Continuity nursing helped my family in our darkest PICU moments

Senators start work on Medicare physician payment reform

hotspot

Medicare Advantage proposed rates disappoint insurers

Gilead might be held responsible for not developing a drug

Patients, doctors are clashing about side effects of hormonal birth control

Robert F. Kennedy is pitching centrism on health, even on abortion

Biogen Alzheimer’s drug launch off to slow start

The Readout: Gilead, Bernie Sanders, and other pharma news

focus

explore

focus

leisure time